The cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively.
The cannabis sector showed some weakness last week, and the Horizons Marijuana Life Sciences ETF (HMMJ) lost 3.0% while the ETFMG Alternate Harvest ETF (MJ) lost 3.4%.
In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year.
Insys Therapeutics generated total revenues of $23.46 million in the second quarter of 2018 as compared to $42.58 million in the second quarter of 2017.
Heron Therapeutics (HRTX) stock surged after the company announced it had received breakthrough designation from the FDA for its postoperative pain management drug, HTX-011.
Financial performance In 3Q17, Cara Therapeutics (CARA) incurred $9.6 million in research and development expenses, compared with $9.1 million in 3Q16. This fall in expenses was due to a $3.1 million decrease in expenses for oral CR845’s Phase 2B clinical trial, and partially offset by increased expenses for its intravenous CR845 safety study. Meanwhile, the company’s general and administrative expenses rose from […]
Oral CR845 for treating chronic kidney disease–associated pruritus In July 2017, Cara Therapeutics (CARA) announced the results from a Phase 1 safety and pharmacokinetics study of oral CR845 in patients with chronic kidney disease (or CKD) undergoing hemodialysis. The results showed that the four dosage strengths evaluated in the study were well tolerated. In October […]
Intravenous CR845 for pruritus Pruritus is associated with chronic conditions such as chronic kidney disease (or CKD), atopic dermatitis, eczema, cholestatic liver disease, and psoriasis. Based on CR845’s effectiveness on the peripheral nervous system and immune cells, as well as its anti-pruritic potency, Cara Therapeutics (CARA) believes the drug has the potential to treat pruritus […]
Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus.
